At LEON, our focus is on delivering innovation in drug development through excellence in nano science. From concept to Good Manufacturing Practice (GMP), we provide the insight and intelligence needed to successfully deliver optimised Active Pharmaceutical Ingredients (APIs) to market, whether for novel or existing formulations.

We are proud to have built up a formidable team with a blend of talents, all dedicated to the application of nanoparticle technology. Working collaboratively with clients and partners, we are dedicated to support them in uncovering new opportunities, securing greater market share, and achieving sustained higher margins.


Deep international experience in pharmaceutical & biotech sectors with proven track records in start ups, own companies, small, medium and large organizations supported by an experienced Supervisory Board.

Christian Nafe

Christian brings a wealth of experience and expertise in the management of successful businesses.
Having held board-level positions including CEO and CFO at global companies for more than 25 years, Christian is equipped with a wealth of senior experience in business management and finance. With a focus on life sciences, he has successfully led the delivery of several M&A’s, financing rounds as well as license contracts and supply agreements.

Andrea Cusack

A high performing, energetic leader, Andrea offers over 25 years’ experience in the life science sector. Having acquired a novel blend of technical and commercial expertise in global healthcare organisations across Pharma, Consumer Health, Medical Device, Biotech and Life Sciences, Andrea is uniquely positioned to lead leon and its clients into the next stage of development.

Dr Frank Stieneker

Frank is a Qualified Person (QP) and a leading authority in pharmaceutics, biotechnology and validation of aseptic processes. He has Co-founded a number of companies IFAP AG, GEFAP GmbH and Aukamm Pharma GmbH and lectured in pharmaceutical technology at the University of Frankfurt. As author of one of the first nano particle patents, facilitating one of the first bioprocessing technical transfers and performing one of the first QP releases of a gene transfer IMP, Frank brings more than 30 years of experience within the pharmaceutical industry, life science sectors and academic.

Dr Paul Jenkins

Paul brings more than 25 years of business development and senior management experience in the pharmaceutical and health care industries. As a proactive business development (BD) professional with considerable international knowledge, he has led BD and sales teams in the US, EU, UK and Japan. Furthermore, he has gained a wealth of contracting and alliance management experience. Paul is an immunologist by training, holds a management qualification from London Business School and has served on several Boards of start-up companies.

Massimo Bresciani

Massimo has a wealth of experience from over 25 years in the pharmaceutical sector in senior industrial roles and at the interface between research and commercial application of innovative solutions. Holding an MBA in Business Management, he has acquired multidisciplinary expertise in pharmaceutical development and drug delivery technologies, as well as in the regulatory landscape. In addition, Massimo has lead optimization insights across all preclinical and clinical phases.


Do you want to be part of our team?


Dr Hubert Birner

Hubert is responsible for overall investment strategy and global fund operations at TVM Capital Life Science, and holds a number of chairmanships in leading life sciences companies.

Prior to his current role, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals, having joined from McKinsey & Company’s European healthcare and pharmaceutical practice. As a management consultant, he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Hubert holds a doctoral degree in biochemistry and has an MBA from Harvard Business School.

Dr Frank Mathias

Frank has held leadership positions across the pharmaceutical and biotech industry for more than 25 years.
He is currently Chief Executive Officer of Rentschler Biopharma SE and also Chairman of vfa bio, which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies.

From 2009 until 2016, Frank was Chief Executive Officer of Medigene AG, having joined the company in 2008 as Chief Operating Officer.

Prior to that he worked for Amgen GmbH, Servier Deutschland and Hoechst AG.
He is a graduate of Paris VI University, where he studied immunology.

James C. Gale

The founding partner of Signet Healthcare Partners, James (Jim) has over 30 years of healthcare investing and finance experience.
He is a Managing Director in Signet Fund IV and holds a number of board positions across companies in the healthcare sector.

Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., where he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals). He holds an MBA from the University of Chicago.

Enno Spillner

Enno is Chief Financial Officer and a member of the Management Board of Evotec.

He previously held the roles of Chairman, CEO and CFO of 4SC AG, having joined the company in September 2005 in the capacity of CEO. Before working for 4SC, Enno was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, where his responsibilities included finance and controlling as well as managing investments in the equity portfolio. He held the position of Interim Managing Director at two portfolio companies – ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH – and in 2001, took on the role of Management Partner of BioM VC Fund. Enno earned his Masters in Business from the University of Bamberg, Germany.

Dr Robert Becker

Robert has more than 35 years of experience in the pharmaceutical industry. Earlier in his career, he held various leadership positions at Boehringer-Ingelheim, Eli Lilly and Company Biogen Idec and Aptalis.

In 2014 he founded Impala Pharma Consulting supporting academic and NGO institutions, Start-up companies, Pharma and Biotech companies from idea generation to launch. He has a strong background in pharmaceutical product development, established a broad vendor network for API, DP and analytical methods development and created strategic partnerships with major collaboration partners for small molecule and protein formulation development. Robert is an expert in process chemistry, design and development of formulations across all pharmaceutical dosage forms and drug delivery systems. Robert is a Chemist by training with focus on Physical Chemistry and holds his Ph.D. from the Technical University Munich, Germany.

Dr Gerhard Ries

Gerhard has more than 20 years’ experience in global life sciences and venture capital, both as an entrepreneur and investor.

Before founding LifeCare Partners, he was co-founder and Managing Partner of BioMedPartners, where he supervised more than 50 investments and served on the board of more than 20 biotech companies. Prior to that, he was co-founder and Managing Director of InterPharmaLink, a specialist portfolio management consulting company for the pharmaceutical industry, and has also held various positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Gerhard has a Masters and PhD in Molecular Biology from the University of Basel and a Masters in biotechnology from the Fachhochschule Weihenstephan (Munich).

Dr Peter Graf

Peter is Investment Manager at the Venture Capital Unit of BayBG, one of the largest mid-cap investment firms in Germany, with a portolio of more than 500 companies and shareholders including, among others, Deutsche Bank, Commerzbank, LfA Förderbank Bayern and Unicredit/Hypovereinsbank.

Peter has extensive experience in the IT sector, having founded a Munich- and Berlin-based IT company and delivered successful software projects for clients such as BMW, Diebel’s and Hypovereinsbank. During his time at the Max Planck Institute of Biochemistry, Peter worked on the mechanisms of cell cycle regulation, generating and analysing whole genome data of protein-binding sites and gene-expression data using a combination of wet lab and bioinformatic methods. He holds an degree in Agricultural Sciences and Molecular Biology (with high distinction) and obtained his PhD from LMU Munich.


We are supported by a strong consortium of investors, having secured significant additional backing in our recent Series B funding round. Among others our leading investors are:


“Design Thinking” combined with our expertise, know-how and our world class network partners leads to better patient outcomes faster.

Evotec SE

Formalising its Discovery and Development Services in 2002, Evotec SE creates partnerships to further research in multiple health fields, including cancer and infectious diseases. LEON and Evotec’s strategic partnership will maximise the effectiveness of clinical and commercial nano-medicine development.

The Goodman Pediatric Formulations Centre

The Goodman Pediatric Formulations Centre (GPFC) is a not-for-profit organisation that strives to improve access to child-friendly medicines and promote practices that increase the safety of medicines administered to children.


CoreRx is a CDMO that focuses on early phase drug product development. It offers an integrated service for the development, manufacturing, and testing of solid, semi-solid and liquid dosage forms.

Instillo Group

The Instillo Group is a network of independent companies, offering expertise to both national and international companies in more than 20 countries. Through its partnership with the Instillo Group, leon is the exclusive licence owner of the MicroJet Reactor (MJR®) in Pharma.